Celldex Therapeutics vs Outlook Therapeutics
Celldex Therapeutics reported revenue of $2 million in fiscal 2025, about the same as Outlook Therapeutics' $1 million in fiscal 2025. Celldex Therapeutics had an operating margin of -18599.8%, against -4744.2% at Outlook Therapeutics. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Celldex Therapeutics | Outlook Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $2M | $1M |
| Revenue growth | −78.0% | — |
| Revenue growth a year, last 5 years | −27.3% | — |
| Gross margin | 87.1% | 4.0% |
| Operating margin | −18,599.8% | −4,744.2% |
| Net margin | −16,748.0% | −4,416.2% |
| Free cash flow | −$214M | — |
| Free cash flow margin | −13,829.1% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.1% | 87.6% |
| Last close | $27.96 | $0.40 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $121,231 | bought $7.9 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Celldex TherapeuticsOutlook Therapeutics
Operating margin
Percent of revenue
Celldex TherapeuticsOutlook Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsOutlook Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and Outlook Therapeutics pages.